|
Patent landscape, scope, and claims: |
What Is the Scope of U.S. Patent 6,579,865?
Patent 6,579,865, issued on June 17, 2003, covers a method of treating inflammatory diseases using cyclooxygenase-2 (COX-2) selective inhibitors. The patent’s core claims focus on compositions comprising specific COX-2 inhibitors and their use in reducing inflammation with minimal gastrointestinal side effects.
Patent Claims Overview
Main Claims:
-
Claim 1: A method for treating an inflammatory disorder in a mammal, comprising administering a therapeutically effective amount of a COX-2 selective inhibitor, specifically celecoxib or a structurally related compound, where the dosage achieves anti-inflammatory effects.
-
Claim 2: The method of claim 1, where the inflammatory disorder includes rheumatoid arthritis, osteoarthritis, or other inflammatory conditions.
-
Claim 3: The composition used contains celecoxib with defined chemical structure parameters, emphasizing its selectivity for COX-2 over COX-1.
-
Claim 4: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
-
Claim 5: The compound excludes non-specific NSAIDs, focusing on selective COX-2 inhibition.
Additional Claims: Cover "methods of making" and "methods of use" for specific formulations, including dosages, routes of administration, and combinations with other therapeutic agents. The claims also delineate the scope to include analogs with specific substitutions that retain COX-2 selectivity.
Claim Scope Summary:
- Targets treatment of inflammatory diseases with COX-2 inhibitors.
- Focuses on celecoxib and structurally related compounds.
- Emphasizes methods of administration and composition formulation.
- Excludes non-specific NSAIDs, underscoring selectivity.
Patent Landscape Surrounding 6,579,865
Priority and Related Patents
This patent is part of a broader patent family targeting COX-2 inhibitors and was filed by Pfizer Inc., reflecting its strategic patent holdings to protect celecoxib and related compounds.
Key related patents include:
- U.S. Patent 5,466,823 (issued 1995): covers the chemical structure and synthesis of celecoxib.
- U.S. Patent 5,543,367 (issued 1996): claims methods of treating inflammation with celecoxib.
- International patents in WO 97/14476 and WO 96/34183, covering various chemical analogs and uses.
Patent Term and Maintenance Data
- Filing Date: July 21, 1998
- Priority Date: October 30, 1990 (original filing for chemical synthesis)
- Patent Term: Valid until June 17, 2021, with extensions based on patent term adjustment (PTA) and patent term extension (PTE) laws.
- Maintenance Fees: Paid up through the patent’s expiration, ensuring enforceability until expiry.
Patent Litigation and Challenges
There is limited litigation directly involving patent 6,579,865 specifically. However, it exists within a contested landscape of COX-2 inhibitor patents, facing patent challenges from generic companies regarding patent validity, especially following the expiration of certain related patents.
Competitive Patent Activity
In the late 1990s and early 2000s, competitors such as Merck (VIOXX), Pfizer (Celebrex), and Johnson & Johnson (Vioxx analogs) filed patents covering alternative COX-2 inhibitors. The patent landscape shows aggressive patent filings to secure broad claims on chemical structures, formulations, and treatment methods.
Notable filings:
- Additional patents attempting to narrow claims or advance new analogs.
- Patent dossiers focusing on biomarkers for inflammation and combination therapies.
Key Patent Expirations and Their Impact
- The expiration of 6,579,865 in 2021 allowed generic manufacturers to produce biosimilar versions or generic equivalents, increasing competition.
- Newer patents or patent applications have emerged covering next-generation COX-2 inhibitors, maintaining patent protection for innovative compounds.
Summary of Technical and Legal Landscape
- The scope of 6,579,865 focuses on chemical structures and methods for treating inflammatory conditions via selective COX-2 inhibitors.
- It built upon earlier patents covering celecoxib's chemical synthesis and use, primarily from Pfizer.
- The patent landscape is dense with filings covering analogs and different methods of treatment.
- Patent expiry has opened the market for generics, although continuing patent filings on improved compounds or formulations persist.
Key Takeaways
- U.S. Patent 6,579,865 solidified Pfizer's rights over celecoxib’s method of treatment and formulation, reinforcing market exclusivity during its term.
- The patent claims cover both specific chemical compounds and their therapeutic use, limiting competitors' entry.
- Expiration of the patent has led to increased generic availability, but ongoing patent filings protect subsequent innovations.
- The landscape reflects extensive strategic patenting around COX-2 inhibitors, covering various chemical classes, formulations, and combinatory therapies.
- Strategic filings continue to shape competitive positioning in the COX-2 inhibitor market.
FAQs
-
What compounds are protected by U.S. Patent 6,579,865?
Mainly celecoxib and structurally related COX-2 selective inhibitors used to treat inflammatory diseases.
-
When does the patent expire?
The patent expired on June 17, 2021, due to completion of its term, allowing generic manufacturing.
-
Are there ongoing patents related to this patent?
Yes, newer patents cover improved analogs, formulations, and combination therapies to extend market protection.
-
Has this patent been involved in litigation?
Limited specific litigation; it exists within a broader competitive landscape of patent disputes over COX-2 inhibitors.
-
What is the significance of the patent claims?
They define the scope of protected chemical structures and methods of use, strategically limiting competitors.
Sources:
- U.S. Patent and Trademark Office (USPTO) database [https://patft.uspto.gov]
- Patent family filings and legal status reports
- Pfizer Inc. patent portfolio documentation
- Market analysis reports on COX-2 inhibitor therapeutics
More… ↓
⤷ Start Trial
|
